Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.